Learn all about the VICTUS® Femtosecond Laser Platform

Learn more about the new TECHNOLAS® TENEO™ 317 Excimer Laser

Upcoming Events

Euretina /ESCRS 
12th – 17th September, 2014
London, UK
Bausch + Lomb Technolas Satellite Symposia (PDF)

AAO - American Academy of Ophthalmology
18th – 21st October, 2014
Chicago, USA

What is New

Some of the products and/or specific features as well as the procedures featured on this website may not be approved in your country, including Canada, and thus may not be available there. The VICTUS platform has CE Marking for capsulotomy, lens fragmentation, arcuate corneal incisions, corneal incisions, LASIK flap, INTRACOR®, penetrating keratoplasty and intrastromal channel incisions for intracorneal ring segments. Indications may vary by country. In the United States, the VICTUS Femtosecond Laser Platform is indicated for use in the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea; for anterior capsulotomy during cataract surgery; and for the creation of cuts / incisions in the cornea in patients undergoing cataract surgery or other ophthalmic treatment requiring cuts/incisions in the cornea and for laser assisted fragmentation during cataract surgery for nuclear cataracts, not for fragmentation of posterior subcapsular and cortical cataracts. The TECHNOLAS TENEO 317 is CE marked but NOT approved for use in the US. The TECHNOLAS TENEO 317 is not approved in all countries.
SUPRACOR excimer laser treatment and INTRACOR are CE marked but NOT approved for use in the US. SUPRACOR excimer laser treatment and INTRACOR and are not approved in all countries. Please contact our regional representative regarding individual availability in your respective market.

© 2012-2014 TECHNOLAS Perfect Vision GmbH. All Rights Reserved
A Bausch + Lomb Company
powered by DASAT